Patents by Inventor Gabriel M. Gutierrez

Gabriel M. Gutierrez has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Anti-malarial compositions
    Patent number: 10160802
    Abstract: This disclosure provides antibodies that are useful for preventing and/or treating malaria. The epitope to which the antibodies bind is in close proximity to the conserved proteolytic cleavage site of P. falciparum circumsporozoite protein (CSP), and the antibodies provided in this disclosure can prevent cleavage and inhibit P. falciparum sporozoites from invading the liver.
    Type: Grant
    Filed: February 29, 2016
    Date of Patent: December 25, 2018
    Assignees: LEIDOS, INC., THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
    Inventors: Gabriel M. Gutierrez, James Pannucci, Amy Noe, Steve Chienwen Huang, Scott Winram, Annie Xiaoyan Mo
  • PD-1 and CTLA-4 Dual Inhibitor Peptides
    Publication number: 20180339044
    Abstract: This disclosure provides peptides which have a strong affinity for the checkpoint receptor “programmed death 1” (PD-1). These peptides block the interaction of PD-1 with its ligand PD-L1 as well as the interaction of CTLA4 with CD86 and can therefore be used for various therapeutic purposes, such as inhibiting the progression of a hyperproliferative disorder, including cancer; treating infectious diseases; enhancing a response to vaccination; treating sepsis; and promoting hair re-pigmentation or lightening of pigmented skin lesions.
    Type: Application
    Filed: May 25, 2018
    Publication date: November 29, 2018
    Inventors: Gabriel M. Gutierrez, Vinayaka Kotraiah, Timothy W. Phares, James Pannucci
  • PD-1 Peptide Inhibitors
    Patent number: 10098950
    Abstract: This disclosure provides peptides which have a strong affinity for the checkpoint receptor “programmed death 1” (PD-1). These peptides block the interaction of PD-1 with its ligand PD-L1 and can therefore be used for various therapeutic purposes, such as inhibiting the progression of a hyperproliferative disorder, including cancer, treating infectious diseases, enhancing a response to vaccination, and treating sepsis.
    Type: Grant
    Filed: September 15, 2017
    Date of Patent: October 16, 2018
    Assignee: Leidos, Inc.
    Inventors: Gabriel M. Gutierrez, Vinayaka Kotraiah, James Pannucci, Ramses Ayala
  • PD-1 Peptide Inhibitors
    Publication number: 20180200328
    Abstract: This disclosure provides peptides which have a strong affinity for the checkpoint receptor “programmed death 1” (PD-1). These peptides block the interaction of PD-1 with its ligand PD-L1 and can therefore be used for various therapeutic purposes, such as inhibiting the progression of a hyperproliferative disorder, including cancer; treating infectious diseases; enhancing a response to vaccination; treating sepsis; and promoting hair re-pigmentation or lightening of pigmented skin lesions.
    Type: Application
    Filed: February 27, 2018
    Publication date: July 19, 2018
    Inventors: Gabriel M. Gutierrez, Vinayaka Kotraiah, James Pannucci, Ramses Ayala
  • PD-1 Peptide Inhibitors
    Publication number: 20180185474
    Abstract: This disclosure provides peptides which have a strong affinity for the checkpoint receptor “programmed death 1” (PD-1). These peptides block the interaction of PD-1 with its ligand PD-L1 and can therefore be used for various therapeutic purposes, such as inhibiting the progression of a hyperproliferative disorder, including cancer, treating infectious diseases, enhancing a response to vaccination, and treating sepsis.
    Type: Application
    Filed: March 1, 2018
    Publication date: July 5, 2018
    Inventors: Gabriel M. Gutierrez, Vinayaka Kotraiah, James Pannucci, Ramses Ayala
  • Malaria vaccine
    Patent number: 9943580
    Abstract: Embodiments are directed to malaria vaccines comprising a bacteriophage VLP displaying a heterologous peptide identified by affinity selection as an anti-malaria mimotope.
    Type: Grant
    Filed: September 11, 2014
    Date of Patent: April 17, 2018
    Assignees: STC.UNM, LEIDOS, INC.
    Inventors: David S. Peabody, Bryce Chackerian, James Pannucci, Gabriel M. Gutierrez, Amy Rene Noe, Scott Budd Winram, Steve Chienwen Huang
  • PD-1 Peptide Inhibitors
    Publication number: 20180071385
    Abstract: This disclosure provides peptides which have a strong affinity for the checkpoint receptor “programmed death 1” (PD-1). These peptides block the interaction of PD-1 with its ligand PD-L1 and can therefore be used for various therapeutic purposes, such as inhibiting the progression of a hyperproliferative disorder, including cancer, treating infectious diseases, enhancing a response to vaccination, and treating sepsis.
    Type: Application
    Filed: September 15, 2017
    Publication date: March 15, 2018
    Inventors: Gabriel M. Gutierrez, Vinayaka Kotraiah, James Pannucci, Ramses Ayala
  • MALARIA VACCINE
    Publication number: 20160228525
    Abstract: Embodiments are directed to malaria vaccines comprising a bacteriophage VLP displaying a heterologous peptide identified by affinity selection as an anti-malaria mimotope.
    Type: Application
    Filed: September 11, 2014
    Publication date: August 11, 2016
    Inventors: David S. PEABODY, Bryce CHACKERIAN, James PANNUCCI, Gabriel M. GUTIERREZ, Amy Rene NOE, Scott Budd WINRAM, Steve Chienwen HUANG
  • Anti-Malarial Compositions
    Publication number: 20160176955
    Abstract: This disclosure provides antibodies that are useful for preventing and/or treating malaria. The epitope to which the antibodies bind is in close proximity to the conserved proteolytic cleavage site of P. falciparum circumsporozoite protein (CSP), and the antibodies provided in this disclosure can prevent cleavage and inhibit P. falciparum sporozoites from invading the liver.
    Type: Application
    Filed: February 29, 2016
    Publication date: June 23, 2016
    Inventors: Gabriel M. Gutierrez, James Pannucci, Amy Noe, Steve Chienwen Huang, Scott Winram, Annie Xiaoyan Mo
  • Anti-malarial compositions
    Patent number: 9321834
    Abstract: This disclosure provides antibodies that are useful for preventing and/or treating malaria. The epitope to which the antibodies bind is in close proximity to the conserved proteolytic cleavage site of P. falciparum circumsporozoite protein (CSP), and the antibodies provided in this disclosure can prevent cleavage and inhibit P. falciparum sporozoites from invading the liver.
    Type: Grant
    Filed: December 5, 2013
    Date of Patent: April 26, 2016
    Assignees: LEIDOS, INC., THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
    Inventors: Gabriel M. Gutierrez, James Pannucci, Amy Noe, Steve Chienwen Huang, Scott Winram, Annie Xiaoyan Mo
  • ANTI-MALARIAL COMPOSITIONS
    Publication number: 20150158941
    Abstract: This disclosure provides antibodies that are useful for preventing and/or treating malaria. The epitope to which the antibodies bind is in close proximity to the conserved proteolytic cleavage site of P. falciparum circumsporozoite protein (CSP), and the antibodies provided in this disclosure can prevent cleavage and inhibit P. falciparum sporozoites from invading the liver.
    Type: Application
    Filed: December 5, 2013
    Publication date: June 11, 2015
    Applicant: Leidos, Inc.
    Inventors: Gabriel M. Gutierrez, James Pannucci, Amy Noe, Steve Chienwen Huang, Scott Winram